HomeCompareRNRTY vs JNJ

RNRTY vs JNJ: Dividend Comparison 2026

RNRTY yields 4.54% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $8.5K in total portfolio value· pulled ahead in Year 7
10 years
RNRTY
RNRTY
● Live price
4.54%
Share price
$7.09
Annual div
$0.32
5Y div CAGR
-25.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.8K
Annual income
$27.91
Full RNRTY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RNRTY vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRNRTYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RNRTY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RNRTY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RNRTY
Annual income on $10K today (after 15% tax)
$386.06/yr
After 10yr DRIP, annual income (after tax)
$23.72/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,962.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RNRTY + JNJ for your $10,000?

RNRTY: 50%JNJ: 50%
100% JNJ50/50100% RNRTY
Portfolio after 10yr
$26.0K
Annual income
$2,358.66/yr
Blended yield
9.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RNRTY
No analyst data
Altman Z
5.8
Piotroski
8/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RNRTY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRNRTYJNJ
Forward yield4.54%2.13%
Annual dividend / share$0.32$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-25.1%28%
Portfolio after 10y$21.8K$30.3K
Annual income after 10y$27.91$4,689.40
Total dividends collected$1.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RNRTY vs JNJ ($10,000, DRIP)

YearRNRTY PortfolioRNRTY Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,040$340.19$10,592$272.30+$448.00RNRTY
2$12,076$262.90$11,289$357.73+$787.00RNRTY
3$13,123$201.30$12,123$472.89+$1.0KRNRTY
4$14,194$153.12$13,141$629.86+$1.1KRNRTY
5$15,304$115.94$14,408$846.81+$896.00RNRTY
6$16,462$87.50$16,021$1,151.60+$441.00RNRTY
7← crossover$17,681$65.89$18,122$1,588.22$441.00JNJ
8$18,968$49.53$20,930$2,228.20$2.0KJNJ
9$20,333$37.20$24,792$3,191.91$4.5KJNJ
10$21,784$27.91$30,274$4,689.40$8.5KJNJ

RNRTY vs JNJ: Complete Analysis 2026

RNRTYStock

Reunert Limited operates in the fields of electrical engineering, information communication technologies (ICT), and applied electronics in South Africa, Australia, Lesotho, India, Mauritius, the United States, and Zambia. The company's Electrical Engineering segment designs, manufactures, installs, and maintains power cables; copper and optical fiber telecommunications cables and cable ducts; low-voltage electrical distribution, protection, and control equipment and high and medium-voltage switchgear; copper casted rods; and aluminum conductors. It serves mining, utilities, municipalities, parastatals, and building industries. Its ICT segment provides multi-functional printer devices, managed print software and solutions, production printing devices, document management solutions, smart solutions, surveillance and access controls, and telephony and connectivity solutions; and asset-backed financial solutions. This segment also provides voice, data, and hosted services through fixed-line and wireless access circuits; cloud-based virtual private branch exchange services; and hosted call recording, geographic number portability, and business Internet access products; and telecommunications services, as well as communications solutions. It serves corporate and retail customers, small and medium-sized enterprises, government, and state-owned entities (SOEs). The company's Applied Electronics segment offers search and tracking radar systems and subsystems; secure communication systems; secure network-centric solutions; cryptographic products and solutions; electronic components; remote controlled stabilized weapons platforms; energy engineering and storage solutions; and robotics systems. It serves corporates, municipalities, governments, local and international defense forces, and mining houses. The company was founded in 1888 and is headquartered in Johannesburg, South Africa.

Full RNRTY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RNRTY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RNRTY vs SCHDRNRTY vs JEPIRNRTY vs ORNRTY vs KORNRTY vs MAINRNRTY vs ABBVRNRTY vs MRKRNRTY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.